EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real‐world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study

Miguel-Ángel Berciano-Guerrero iD, Elisabeth Pérez-Ruiz iD, Ainara Soria, Javier Medina Martínez, Pablo Ayala de Miguel iD, Eva Muñoz-Couselo iD, Lorena Bellido, Rafael López Castro, Enrique Espinosa iD, Lourdes Gutiérrez Sanz, Pablo Cerezuela-Fuentes iD, Almudena García Castaño und 18 weitere

Cancer · 2026

DOI: 10.1002/cncr.70497 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2026. Verfasst von Miguel-Ángel Berciano-Guerrero und 29 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital Regional Universitario, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Málaga, Spain. Hauptthemen laut MEDLINE: Melanoma, Antineoplastic Combined Chemotherapy Protocols, Immunotherapy. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Spanish Multidisciplinary Melanoma Group, BMS, Incyte.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chemotherapy schemes have historically shown low efficacy in patients with metastatic melanoma and have been replaced by immunotherapy and targeted therapy. This work aimed to study whether chemotherapy remains an option after progression to immunotherapy in specific contexts.

Methods

The GEM1801 registry includes patients with advanced melanoma in Spain. For this substudy, patients with metastatic melanoma who received chemotherapy after immunotherapy were selected. Baseline characteristics and treatment outcomes were analyzed.

Results

Of the 1316 patients included, with a median time of 4.8 months (range, 0.0–35.8) from the first immunotherapy, 92 received chemotherapy: 12 after adjuvant immunotherapy (cohort A), 45 subsequently to immunotherapy (cohort B), and 35 after receiving bridge therapies (cohort C). The median age was 66 years (range, 35–94), and 55.4% of the patients were male. Most patients had an Eastern Cooperative Oncology Group (ECOG) status of ≤1 (65.2%), whereas only 21.7% had ECOG 2. Among the patients, 54.3% had elevated lactate dehydrogenase levels. Chemotherapy regimens received were taxane/platinum‐based therapies (47.8%), dimethyl triazeno imidazol carboxamide (DTIC) (26.1%), fotemustine (17.4%), and other alkylating agents such as temozolomide (8.7%). With a median follow‐up of 31.9 months, the objective response rate was 12%, the median progression‐free survival was 3.5 months (95% CI, 2.9–4.8), and the median overall survival was 6.1 months (95% CI, 5.3–9.2).

Conclusions

As in previous studies, patients treated with chemotherapy after immunotherapy failure had poor outcomes, similar to those from pre‐immunotherapy era, and should be used when no other options are available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaAntineoplastic Combined Chemotherapy ProtocolsImmunotherapyHumansMaleAgedFemaleMiddle AgedSpainAdultAged, 80 and overBridge TherapyRegistriesTreatment Outcome

Stichwörter der Autor:innen

chemotherapyimmune checkpoint inhibitorsmetastatic melanomareal‐world

Autor:innen und Institutionen

  • Medical Oncology Department, Hospital Regional Universitario, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Málaga, Spain.
  • Medical Oncology Intercenter Unit, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain.
  • Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA-BIONAND), Málaga, Spain.
  • University of Málaga, Málaga, Spain.
  • Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Medical Oncology Department, Hospital Universitario de Toledo, Toledo, Spain.

ORCID-Profile: Miguel-Ángel Berciano-Guerrero, Elisabeth Pérez-Ruiz, Pablo Ayala de Miguel, Eva Muñoz-Couselo, Enrique Espinosa, Pablo Cerezuela-Fuentes, Begoña Campos Balea, Alberto Jacobo Cunquero Tomás, Luis Antonio Fernández, Joaquín Fra Rodríguez, Salvador Martín Algarra, Iván Márquez-Rodas

Förderung

  • Spanish Multidisciplinary Melanoma Group
  • BMS
  • Incyte
  • MSD
  • Mural Oncology
  • Novartis
  • Pierre Fabre
  • Roche

Zitieren

APA

Berciano-Guerrero, M. Á., Pérez-Ruiz, E., Soria, A., Medina Martínez, J., Ayala de Miguel, P., Muñoz-Couselo, E., Bellido, L., López Castro, R., Espinosa, E., Gutiérrez Sanz, L., Cerezuela-Fuentes, P., García Castaño, A., Crespo, G., Puértolas, T., Aguado de la Rosa, C., Corral Subias, M., Campos Balea, B., Bujosa Rodríguez, A., Navarro Pérez, V., …, & Márquez-Rodas, I. (2026). Real‐world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study. Cancer. https://doi.org/10.1002/cncr.70497

Vancouver

Berciano-Guerrero MÁ, Pérez-Ruiz E, Soria A, Medina Martínez J, Ayala de Miguel P, Muñoz-Couselo E, et al. Real‐world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study. Cancer. 2026. doi:10.1002/cncr.70497

BibTeX
@article{BercianoGuerrero2026,
  author = {Berciano-Guerrero, Miguel-Ángel and Pérez-Ruiz, Elisabeth and Soria, Ainara and Medina Martínez, Javier and Ayala de Miguel, Pablo and Muñoz-Couselo, Eva and Bellido, Lorena and López Castro, Rafael and Espinosa, Enrique and Gutiérrez Sanz, Lourdes and Cerezuela-Fuentes, Pablo and García Castaño, Almudena and Crespo, Guillermo and Puértolas, Teresa and Aguado de la Rosa, Carlos and Corral Subias, Mónica and Campos Balea, Begoña and Bujosa Rodríguez, Aida and Navarro Pérez, Victor and Lecumberri, María José and García Arroyo, Francisco Ramón and Cunquero Tomás, Alberto Jacobo and Mujika, Karmele and Fernández, Luis Antonio and Villa Guzmán, José Carlos and Hernández, Berta and Fra Rodríguez, Joaquín and Manzano, José Luis and Martín Algarra, Salvador and Márquez-Rodas, Iván},
  title = {Real‐world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70497}
}
Kostenlos starten →